Pediatric drug development: A perspective from the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI)

Investigational New Drugs

Volumn 14, Issue 1, 1996, Pages 11-22

  Smith, Malcolm ^a   Ho, Peter T C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bryostatin; Cyclin dependent kinases; Differentiation agents; Isoprenylation; Pediatric; Phase I; Protein kinase C; Trial design

Indexed keywords

9 AMINOCAMPTOTHECIN; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CELL PROTEIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 6; MERCAPTOPURINE; MILODISTIM; MIVOBULIN ISETHIONATE; PACLITAXEL; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; RETINOIC ACID; TEMOZOLOMIDE; TIAZOFURIN; TIOGUANINE; TOPOTECAN; XOMAZYME;

CANCER RESEARCH; CANCER THERAPY; CELL CYCLE; CHILDHOOD CANCER; CLINICAL TRIAL; DRUG DESIGN; DRUG MECHANISM; DRUG TARGETING; HUMAN; MAXIMUM PERMISSIBLE DOSE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

EID: 0029789293     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00173678     Document Type: Review

References (23)

1. Marsoni S, Ungerleider R, Hurson S, Simon R, Hammershaimb L: Tolerance of antineoplastic agents in children and adults. Cancer Treat Rep 64:1263-1269, 1985
2. Pratt C: The conduct of phase I-II clinical trials in children with cancer. Med Pediatr Oncol 19:304-309, 1991
3. Balis F, Holcenberg J, Poplack D: General principles of chemotherapy. In: Pizzo P, Poplack D (eds) Principles and Practice of Pediatric Oncology. 2nd ed. Philadelphia: JB Lippincott Company, 1993, pp 197-245
4. O'Flaherty E: Physiologic changes during growth and development. Environ Health Perspect 102(Suppl 11): 103-106, 1994
5. Smith M, Adamson P, Balis F et al.: Phase I and pharmacokinetic evaluation of all-trans retinoic acid in pediatric patients. J Clin Oncol 10:1666-1673, 1992
6. Mahmoud H, Hurwitz C, Roberts W, Santana V, Ribeiro R, Krance R: Tretinoin toxicity in children with acute promyelocytic leukaemia. Lancet 342:1394-1395, 1993
7. Lee J, Newman R, Lippman S et al.: Phase I evaluation of all-trans-retinoic acid in adults with solid tumors. J Clin Oncol 11:959-966, 1993
8. Adamson P, Pitot H, Balis F, Rubin J, Murphy R, Poplack D: Variability in the oral bioavailability of all-trans retinoic acid. J Natl Cancer Inst 85:993-996, 1993
9. Hurwitz C, Relling M, Weitman S et al.: Phase I trials of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group study. J Clin Oncol 11:2324-2329, 1993
10. Sonnichsen D, Hurwitz C, Pratt C, Shuster J, Relling M: Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 12:532-538, 1994
11. Tubergen D, Pratt C, Stewart C, Vietti T: Phase I study of topotecan in children with refractory solid tumors: a Pediatric Oncology Group study. Proc Am Soc Clin Oncol 13:167 (abstr), 1994
12. Saylors R, Stewart C, Wall D, Bell B, Vietti T: Phase I trial of topotecan plus cyclophosphamide in children with refractory or recurrent solid tumors: a Pediatric Oncology Group study. Proceedings of ASPH/O 4:24-25 (abstr), 1995
13. Ries L, Miller R, Smith M: Cancer in children (ages 0-14 and ages 0-19). In: Miller B, Ries L, Hankey B (eds) SEER Cancer Statistics Review 1973-1990. Bethesda: National Cancer Institute, 1993: vol NIH Pub. No. 93-2789)
14. Houghton P, Horton J, Houghton J: Drug sensitivity and resistance in the xenograft model. In: Maurer H, Ruymann F, Pochedly (eds) Rhabdomyosarcoma and Related Tumors in Children and Adolescents. Boca Raton: CRC Press, 1991, pp 187-203
15. Houghton J, Cook R, Lutz P et al.: Childhood rhabdomyosarcoma xenografts: responses to DNA-interacting agents and agents used in current clinical therapy. Eur J Cancer Clin Oncol 20:955-960, 1984
16. Houghton P, Cheshire P, Myers L, Stewart C, Synold T, Houghton J: Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 31:229-239, 1992
17. Houghton P, Cheshire P, Hallman J, Bissery M, Mathieu-Boue A, Houghton J: Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino)-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res 53:2823-2829, 1993
18. Jansen B, Uckun F, Jaszcz W, Kersey J: Establishment of a human t(4;11) leukemia in severe combines immunodeficient mice and successful treatment using antiCD 19 (B43)-pokeweed antiviral protein immunotoxin. Cancer Res 52:406-412, 1992
19. Uckun F, Chelstrom L, Finnegan D et al.: Effective immunochemotherapy of CALLA+Cu+human Pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide. Blood 79:3116-3129, 1992
20. Friedman H, Colvin O, Ludeman S et al.: Experimental chemotherapy of human medulloblastoma with classical alkylators. Cancer Res 46:2827-2833, 1986
21. Friedman H, Colvin O, Skapek S et al.: Experimental chemotherapy of human medulloblastoma cell lines and transplant-able xenografts with bifunctional alkylating agents. Cancer Res 48:4189-4195, 1988
22. Vassal G, Valery C, Venuat A et al.: Characterization of a medulloblastoma xenograft model. Proc Am Assoc Cancer Res 34:54 (abstr), 1993
23. Vassal G, Morizet J, Bissery M et al.: Activity of the camptothecin analogue CPT-11 (Irinotecan) against medulloblastoma xenografts. Proc Am Assoc Cancer Res 35:356 (abstr), 1994